Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P717: Comparison of two different techniques to assess vedolizumab trough levels in adult patients with IBDECCO '18 Vienna
Year: 2018
Authors:

C. Berger1*, C. Christ1, F.-P. Armbruster1, H. Schulze2, A. Dignass2,3, J. Stein3,4, K. Farrag3,4

1Immundiagnostik AG, Bensheim, Germany, 2Agaplesion Markus Krankenhaus, Department of Gastroenterology, Frankfurt/Main, Germany, 3Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany, 4DGD Clinics Sachsenhausen, Frankfurt/Main, Germany

P718: Discrepancies between patients’ preferences and physicians’ preference perception for oral formulations: A real-life surveyECCO '18 Vienna
Year: 2018
Authors:

P. Marchi1*, S. Timeus1, L. Mackenzie-Smith1, P. Le Calvé2, R. Young2

1Tillotts Pharma AG, Rheinfelden, Switzerland, 2Kantar Health, Paris, France

P719: Does radiation to the pelvis portend worse ileal pouch outcomes? An international multi-institution collaborative studyECCO '18 Vienna
Year: 2018
Authors:

A. Lightner1*, A. Spinelli2, N. McKenna1, J. Warusavitarne3, P. Fleshner4

1Mayo Clinic, Colon and Rectal Surgery, Rochester, USA, 2Humanitas Clinical Institute, Colon and Rectal Surgery, Milan, Italy, 3St Marks Hospital, Colon and Rectal Surgery, London, UK, 4Cedars-Sinai Los Angeles, Colon and Rectal Surgery, Los Angeles, USA

P720: Is there a difference in trough levels and immunogenicity between Crohn’s disease and ulcerative colitis patients treated with infliximab?ECCO '18 Vienna
Year: 2018
Authors:

D. Perdigoto, C. Macedo*, F. Portela, S. Lopes, M. Ferreira, M. Ferreira, S. Mendes, L. Tomé

Coimbra Hospital and University Center, Gastroenterology, Coimbra, Portugal

P721: Psychological care is needed and welcomed by patients with inflammatory bowel disease under routine careECCO '18 Vienna
Year: 2018
Authors:

T. Lores1*, C. Goess1, C. Hrycek2, R. Grafton1, J. Hughes1, L. Cronin1, A.L. Burke3, K.L. Collins3, A. Chur-Hansen4, A. Mikocka-Walus5, J.M. Andrews1

1Royal Adelaide Hospital, Department of Gastroenterology, Adelaide, Australia, 2Royal Adelaide Hospital, Department of General Medicine, Adelaide, Australia, 3Royal Adelaide Hospital, Department of Psychology, Adelaide, Australia, 4University of Adelaide, Adelaide, Australia, 5Deakin University, Melbourne, Australia

P722: Trough levels, drug switching and antidrug antibody loss: Analysis of real-life infliximab and adalimumab data in IBDECCO '18 Vienna
Year: 2018
Authors:

D. Ho1, T. Sipponen1,2*, T.S. Jokiranta1,3

1University of Helsinki, Helsinki, Finland, 2Helsinki University Hospital, Gastroenterology, Helsinki, Finland, 3United Medix Laboratories, Helsinki, Finland

P723: Effectiveness and persistence of vedolizumab in patients with Inflammatory bowel Disease: Results from the Belgian REal-LIfe study with VEdolizumab (Be-RELIVE)ECCO '18 Vienna
Year: 2018
Authors:

C. Reenaers1*, A. Cremer2, O. Dewit3, B. de Vroey4, W. Van Moerkercke5, P. Bossuyt6, V. Muls7, J. Imschoot8, S. Block8, A. Hantson8, P. Van Hootegem9

1CHU Liège, Gastroenterology, Liège, Belgium, 2ULB Erasme, Brussels, Belgium, 3UCL, Brussels, Belgium, 44Centre Hospitalier Jolimont, Haine-Saint-Paul, Belgium, 5Algemeen Ziekenhuis Groeninge, Kortrijk, Belgium, 6Imelda GI Clinical Research Centre, Keerbergen, Belgium, 7Centre Hospitalier Universitaire Saint-Pierre, Brussels, Belgium, 8Takeda Belgium, Brussels, Belgium, 9Algemeen Ziekenhuis Sint-Lucas Brugge vzw, Brugge, Belgium

P724: Unchanged infliximab serum concentrations after switching from the originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease: Results from a prospective study (SECURE)ECCO '18 Vienna
Year: 2018
Authors:

A. Strik1*, W. van de Vrie2, J. Bloemsaat-Minekus3, M. Nurmohamed4, P. Bossuyt5, A. Bodelier6, T. Rispens7, Y. van Megen3, G. D'Haens1

1Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 2Albert Schweitzer Hospital, Department of Gastroenterology and Hepatology, Dordrecht, The Netherlands, 3Mundipharma Pharmaceuticals BV, Hoevelaken, The Netherlands, 4Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands, 5Imelda hospital, Bonheiden, Belgium, 6Amphia Hospital Breda Loc. Langendijk, Breda, The Netherlands, 7Academic Medical Center (AMC), Tytgat Institute for Intestinal and Liver Research, Amsterdam, The Netherlands

P725: Ileal pouch excision: A contemporary observational cohortECCO '18 Vienna
Year: 2018
Authors:

G. Worley1,2*, D. Patsouras3, K. Sahnan1,3, S. Adegbola1,3, H. Mahmood3, O. Faiz1,3, S. Clark1,3

1Imperial College London, Department of Surgery and Cancer, London, UK, 2St Mark's Hospital and Academic Institute, Surgical Epidemiology Trials and Outcome Centre, London, UK, 3St Mark's Hospital and Academic Institute, London, UK

P726: Metalloproteinase 3: A new marker for assessing loss of response to infliximab in IBDECCO '18 Vienna
Year: 2018
Authors:

B. Barberio1*, R. D'Incà2, M. Dalla Gasperina1, S. Facchin1, L. Digiglio1, R. Cardin1, G. Lorenzon1, A. Rigo1, G.C. Sturniolo1

1University of Padua, Gastroenterology, Padova, Italy, 2University of Padua, Gastroenterologia, Padova, Italy

P727: Efficacy of vedolizumab (VDZ) by disease localisation in Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

M. Allez1*, F. Braegger2, C. Kempf2, P. Michetti3

1Hôpital Saint-Louis, APHP, INSERM UMRS 1160, Université Denis Diderot, Gastroenterology and Hepatology, Paris, France, 2Takeda Pharmaceuticals International AG, Zurich, Switzerland, 3Gastro-entérologie La Source-Beaulieu and Division of Gastroenterology, Centre Hospitalier Universitaire Vaudois, Crohn’s and Colitis Center, Lausanne, Switzerland

P728: Efficacy of anti-TNF treatment in patients with refractory ulcerative proctitis: Results from a French retrospective multi-centre national cohortECCO '18 Vienna
Year: 2018
Authors:

G. Pineton de Chambrun1*, A. Amiot2, G. Bouguen3, S. Viennot4, R. Altwegg1, E. Louis5, M. Collins6, M. Fumery7, F. Poullenot8, L. Armengol9, A. Buisson10, V. Abitbol11, Y. Bouhnik12, D. Laharie8, P. Seksik13, S. Nancey14, P. Blanc1, M. Nachury15, L. Peyrin-Biroulet16

1Montpellier University Hospital, Gastroenterology, Montpellier, France, 2Henri-Mondor University Hospital, Gastroenterology, Creteil, France, 3Rennes University Hospital, Gastroenterology, Rennes, France, 4Caen University Hospital, Gastroenterology, Caen, France, 5Liège University Hospital, Gastroenterology, Liège, Belgium, 6APHP Paris Sud University , Gastroenterology, Le Kremlin Bicêtre, France, 7Amiens University Hospital, Gastroenterology, Amiens, France, 8Bordeaux University Hospital, Gastroenterology, Bordeaux, France, 9Rouen University Hospital, Gastroenterology, Rouen, France, 10Clermont-Ferrand University Hospital, Gastroenterology, Clermont-Ferrand, France, 11Cochin University Hospital, Gastroenterology, Paris, France, 12Beaujon University Hospital, Gastroenterology, Paris, France, 13Saint-Antoine University Hospital, Gastroenterology, Paris, France, 14Lyon University Hospital, Gastroenterology, Lyon, France, 15Lille University Hospital, Gastroenterology, Lille, France, 16Nancy University Hospital, Gastroenterology, Nancy, France

P729: A ‘real-world’ retrospective multi-centre study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

V. Kronsten1*, M. Colwill1, S. Nayeemuddin2, J. Limdi2,3, C. Selinger4, G. Scott5, L. Al-Hillawi6, S. Salehi6, P. Blaker6, G. Chung-Faye1, A. Kent1, P. Dubois1, B. Hayee1

1Department of Gastroenterology, King's College Hospital NHS Foundation Trust, London, UK, 2Department of Gastroenterology, The Pennine Acute Hospitals NHS Trust, Manchester, UK, 3Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK, 4Department of Gastroenterology, Leeds Teaching Hospitals NHS Trust, Leeds, UK, 5Department of Gastroenterology, East Kent Hospital University Foundation Trust, Margate, UK, 6Department of Gastroenterology, Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, UK

P730: High-dosed intravenous iron replacement therapy does not hinder drug-induced amelioration of disease activity in IBD patients with iron deficiency anaemiaECCO '18 Vienna
Year: 2018
Authors:

J. Stein1,2*, S. Vollmer3, W. Klemm4, K. Nip5, S. Weber-Mangal5, A. Dignass1,6

1Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany, 2DGD Clinics Sachsenhausen, Frankfurt/Main, Germany, 3Gastroenterological practice, Göppingen, Germany, 4Gastroenterological practice, Cottbus, Germany, 5Vifor Pharma Deutschland GmbH, Munich, Germany, 6Agaplesion Markus Krankenhaus, Department of Gastroenterology, Frankfurt/Main, Germany

P731: The impact of thiopurine drugs on the natural history and surgical outcome of ulcerative colitis: A cohort studyECCO '18 Vienna
Year: 2018
Authors:

C. Eriksson1, S. Rundquist1, Y. Cao2, S. Montgomery2, J. Halfvarson1*

1Faculty of Medicine and Health, Örebro University, Örebro, Sweden, 2Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden

P732: Disability in older IBD patientsECCO '18 Vienna
Year: 2018
Authors:

V. Asscher1*, L. Meijer1, S. Waars1, J. Slagboom1, A. Van der Meulen- de Jong1, S. Mooijaart2, J. Maljaars1

1LUMC, Gastroenterology-Hepatology, Leiden, The Netherlands, 2Lumc, Geriatrics and Gerontology, Leiden, The Netherlands

P733: Serum interleukin-6 level predicts future outcomes of infliximab for ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

Y. Nishida*, S. Hosomi, T. Yukawa, K. Otani, Y. Nagami, F. Tanaka, K. Taira, N. Kamata, H. Yamagami, T. Tanigawa, T. Watanabe, Y. Fujiwara

Osaka city university, gastroenterology, Osaka, Japan

P734: Anti-TNFa exposure during pregnancy is not associated with increased infection risk in exposed children during the first year of lifeECCO '18 Vienna
Year: 2018
Authors:

D. Duricová1*, E. Dvorakova1, J. Kozeluhova2, P. Kohout3, K. Mitrova4, M. Durilova5, K. Zarubova4, O. Hradsky4, J. Bronsky4, N. Hradska6, E. Bronska6, N. Machkova1, V. Hruba1, M. Bortlik1, M. Lukas1, K. Malickova1, M. Lukas1

1IBD clinical and research centre, Iscare, Prague, Czech Republic, 2Department of Internal medicine, University Hospital Plzen, Plzen, Czech Republic, 3Department of Internal medicine, Thomayer University Hospital, Prague, Czech Republic, 4Department of Paediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic, 5Department of Paediatric Surgery, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic, 6General paediatrician, Prague, Czech Republic

P735: Incidence of venous thromboembolic complications in controlled trials of inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

S. Vermeire1*, M. Crowther2, V. Pradhan3, A. Banerjee3, F. Cataldi4, K. Gorelick5

1University Hospitals Leuven, Leuven, Belgium, 2McMaster University, Hamilton, Ontario, Canada, 3Pfizer, Cambridge, USA, 4Shire, Lexington, USA, 5Zymo Consulting Group, Newtown Square, USA

P736: Point-of-care infliximab quantification in inflammatory bowel disease in daily practiceECCO '18 Vienna
Year: 2018
Authors:

M.P. Costa Santos*, C. Palmela, C. Gouveia, C. Fidalgo, L. Glória, M. Cravo, J. Torres

Hospital Beatriz Ângelo, Gastroenterology Department, Loures, Portugal